In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Market Access

Set Alert for Market Access

J&J Ups The Tempo In The March Toward Value-based Health Care

Johnson & Johnson's CareAdvantage plan represents a major commitment to working with providers on patient outcomes and reducing costs, and looks beyond the mere price of products. As the group doubles down on value-based health care, its rivals in the medtech devices space will have a lot to reflect upon.

Business Strategies Market Access Reimbursement

Latest From Market Access

Trump's Sights Set On Payers And Pharmas, But Medtechs Must Not Be Complacent

It's been a big month for plans intended to shape the future of health care in the US, with the Trump Administration showcasing its ACA replacement bill and issuing budget proposals. At this stage, it's hard to peg winners and losers and although the focus is squarely on insurance, the medtech sector should guard against complacency, says ZS Associates' Brian Chapman.

Medical Device Regulation

Brexit Podcast: Next Steps For The UK Medtech Industry

Free: In Vivo's Ashley Yeo talks to Association of British Healthcare Industries' Nishan Sunthares and Richard Phillips about the subject that will dominate the thoughts, behavior and business of medical technology companies in the UK for many years to come.

Brexit Regulation

Integrated Health Care Europe-style Is Here – Get Used To It

The era of integrated health care has arrived, at least as far as the European medical technology industry is concerned, where the devices and IVDs industry associations have merged under the umbrella name MedTech Europe. MTE chairman Rob ten Hoedt explains what this means in practice.

Market Access Europe

The 21st Century Cures Act: Allowing The FDA To Address Modern Value Communication Needs

How to prove the real – and implicit – economic value of pharma products to payers and other stakeholders while FDA regulatory approvals adhere to a historically rigid standard of proof based on randomized tests against placebo in a controlled patient population? The 21st Century Cures Act may finally be extending a new path forward that offers legislative endorsement for use of a greater variety of evidence. What the FDA decides to do on this score is emerging as a key issue for biopharma in 2017.

BioPharmaceutical Market Access

Generics In Europe: Search For Greener Pastures?

As global market conditions change and companies seek to fill gaps in their service model to payers and patients, are the business interests of originator and generic firms moving closer toward alignment? Surprisingly, the answer may be yes, according to Medicines for Europe director-general Adrian van den Hoven.

Europe Generic Drugs

Medtechs At The Wheel In New Health Care Landscape

2016 was a year of surprise and change in political circles, but that's nothing new for the medtech industry, which over a number of years has become accustomed to health care systems demanding different and ever-higher levels of service. Smart medtechs have been ahead of the curve, but the whole industry now factors in clients' wider needs in a holistic approach to patient care. Many companies' current M&A policies are already reflecting the changes to come.

M & A Deals
See All